Can efavirenz/emtricitabine/tenofovir (EFV+FTC+TDF, Viraday) be used to treat chronic hepatitis B?

Efavirenz/Emtricitabine/Tenofovir (EFV+FTC+TDF, Viraday) is an antiretroviral drug commonly used to treat human immunodeficiency virus (HIV) infection. This medication is not a first-choice treatment for chronic hepatitis B (hepatitis B), nor is it a treatment for the hepatitis B virus.

Chronic hepatitis B is hepatitis caused by hepatitis B virus (HBV) infection. The goals of treatment for hepatitis B are to reduce viral replication, control disease progression, reduce liver damage, and prevent the development of cirrhosis and liver cancer. The drugs commonly used to treat hepatitis B are mainly antiviral drugs, such as nucleoside or nucleotide reverse transcriptase inhibitors (Nucleos(t)ide analogues, NAs), such as adefovir dipivoxil (adefovir), emtricitabine (entecavir), telbivudine (tenofovir), etc.

Unlike the drugs used to treatHIV, treatment options for hepatitis B are usually single antiviral drugs rather than combination therapies. When determining the treatment plan, doctors will evaluate the patient's condition, liver function status, viral load, degree of liver disease and other factors, and then select the most suitable antiviral drug.

Therefore, if you have chronic hepatitis B, you should consult a professional liver doctor and treat hepatitis B virus according to the doctor's recommendation instead of using efavirenz/emtricitabine/tenofovir (Viraday) for hepatitis B treatment. Remember to carry out treatment according to the doctor's instructions, and conduct regular reexaminations and follow-up visits to ensure the best treatment effect and the stability of liver function.

Efavirenz/Emtricitabine/Tenofovir (EFV+FTC+TDF, Viraday) has not yet been launched in China, so patients cannot purchase it domestically and need to purchase it through overseas purchasing channels. The cheaper ones abroad are mainly Indian generic drugs, which cost around 380 yuan.